Biogen and Eisai Agree to Work Together on Alzheimer’s Therapy Aducanumab

Biogen and Eisai Agree to Work Together on Alzheimer’s Therapy Aducanumab
Biogen  and Eisai have deepened their partnership by agreeing to work together on the continued development of the Alzheimer’s therapy aducanumab (BIIB037), which targets harmful beta amyloid protein clusters. The U.S. and Japanese companies are already collaborating on the development of elenbecestat (E2609) and BAN2401, which also target beta amyloid. Scientists believe beta amyloid accumulations in the brain cause Alzheimer's by damaging nerve cells.  Aducanumab reduces the build-ups, preclinical-trial studies have shown. Until the Biogen-Eisai agreement, Biogen had been developing aducanumab on its own. It licensed the therapy candidate from Neurimmune, which discovered it. The U.S. Food and Drug Administration gave aducanumab Fast Track status in September 2016 — a designation that will accelerate its review of the treatment. The Japanese Ministry of Health, Labor and Welfare gave aducanumab a similar designation in April 2017. “Through this new agreement, we believe we have improved our ability to maximize the value of aducanumab and expand the potential reach of our industry-leading multiple sclerosis portfolio,” Michel Vounatsos, Biogen's chief executive officer, said in a press release. “The ongoing collaboration between Biogen and Eisai leverages our respective expertise and strengths in our efforts to bring new treatments to patients and families affected by Alzheimer’s disease.” “Genetic epidemiological [disease] studies such as the Icelandic genetic research as well as t
Subscribe or to access all post and page content.